Is it time to reconsider molecular response milestones in chronic myeloid leukemia?

Am J Hematol. 2023 Apr;98(4):562-563. doi: 10.1002/ajh.26867. Epub 2023 Feb 9.

Authors

Anushka Walia¹, Vinay Prasad²

Affiliations

¹ School of Medicine, University of California, San Francisco, California, USA.
² Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.

PMID: 36708357
DOI: 10.1002/ajh.26867

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
Leukemia, Myeloid*
Protein Kinase Inhibitors

Substances

Imatinib Mesylate
Protein Kinase Inhibitors